



Genomic Health, Inc.  
Investor Relations Department  
301 Penobscot Dr.  
Redwood City, CA 94063  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: GHDX

Last Trade:	32.04
Trade Time:	11:36 AM ET Mar 22, 2018
Change:	-0.43  (-1.324%)
Day Range	31.94 - 32.58
52-Week Range	26.54 - 37.50
Volume	14,487

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

**Genomic Health, Inc.** (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Mar 15, 2018*

[Landmark TAILORx Results Aid in Assessing the Effect of Chemotherapy in Women with Early-stage Breast Cancer and Oncotype DX Breast Recurrence Score® Results of 11 to 25](#)

*Mar 8, 2018*

[Genomic Health Announces 2017 Fourth Quarter and Year-end Financial Results, Provides 2018 Financial Outlook](#)

*Feb 26, 2018*

[Genomic Health Expands Offering to Prostate Cancer Patients with Launch of Oncotype DX® AR-V7 Nucleus Detect™ Test to Predict Treatment Response in Metastatic Disease](#)

*Feb 22, 2018*

[Genomic Health to Announce Fourth Quarter and Year-End 2017 Financial Results and Host Conference Call on Thursday, March 8, 2018](#)

*Feb 5, 2018*

[Oncotype DX® Genomic Prostate Score™ Test Increases Use of Active Surveillance by 30 Percent in Low-risk Patients, Resulting in Greater Adherence to Guideline-based Care](#)

## Financials & Filings [\[ View all \]](#)

*Mar 14, 2018*

[Annual Report \(10-K\)](#)

*Apr 28, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Nov 9, 2017*

[Quarterly Report \(10-Q\)](#)

*Aug 4, 2017*

[Quarterly Report \(10-Q\)](#)

*May 10, 2017*

[Quarterly Report \(10-Q\)](#)

